Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
LEIDEN, the Netherlands, April 10, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10, 2017 at 15:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
A live webcast of the event will be accessible in the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
